Loftyrock Investment
Profile and portfolio
Loftyrock Investment is the corporate venture arm of Dongkoo Bio & Pharma, a pharmaceutical and biotech company. It was founded in 2022 and is based in South Korea. It invests from seed to Series A. Sectors it names: healthcare and digital health, biotech and life sciences.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series A |
| Sectors | Healthcare and digital health, Biotech and life sciences |
| Geography | North America, Asia |
Sources: S1 Pharmnews: Dongkoo Bio & Pharma subsidiary Loftyrock enters capital markets (2022-02-08).
Where it invests and who leads it
LeadersS1
- Kim Do-hyung (김도형)Chief Executive Officer (대표)Find on LinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Dongkoo Bio & Pharma | Single source | S1 |
| Parent industry | Pharmaceuticals and biotech | Single source | S1 |
| Founded | 2022 | Single source | S1 |
| Headquarters | South Korea | Single source | S1 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S1 |
| Stages | Seed, Series A (inferred from announced rounds) | Estimate | S1 |
Fund vehicles
| Vehicle | Size | Year | Source |
|---|---|---|---|
| Dongkoo Bio-Welcome New Technology Business Investment Partnership No. 1 | Not published | 2022 | S1 |
Recent rounds
Portfolio
Public sources name 5 portfolio companies.S1
Every company on the Loftyrock Investment list
5 companies, as named in the sources cited.S1 Read the firm's list.
- AMCG
- CARV
- Fin Therapeutics
- Valted Seq
- Zigbang
Sources
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Loftyrock Investment or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.